Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Induction and Maintenance in NSCLC
NCT01020786Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Nov 2009; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01020786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01020786.